Fortress Biotech (FBIO)
(Delayed Data from NSDQ)
$1.84 USD
-0.03 (-1.60%)
Updated May 23, 2024 04:00 PM ET
After-Market: $1.84 0.00 (0.00%) 4:52 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Fortress Biotech, Inc. [FBIO]
Reports for Purchase
Showing records 161 - 180 ( 313 total )
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
CUTX-101 Pivotal Data Win; Rolling NDA to Start 4Q20; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Ximino/Targadox Tracker - Week ending 8/21/2020
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Ximino/Targadox Tracker - Week ending 8/14/2020
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
2Q20 Results; Looking Toward Significant Potential Cash Flow
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
BUY: EU is Positive on CUTX-101 Menkes Disease
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J